Altimmune to Present at Upcoming Scientific Conferences

Rhea-AI Summary

Altimmune (Nasdaq: ALT) has announced that its management team will present at two significant scientific conferences in May 2021. Scot Roberts, Ph.D. and Dr. Sarah K. Browne will discuss the AdCOVID™ intranasal COVID-19 vaccine at the World Vaccine Congress from May 4-7, 2021. Additionally, Dr. Scott Harris will present on HepTcell™, a therapy for chronic hepatitis B, at the Chronic Hepatitis B Drug Development Virtual Summit on May 5-6, 2021. Presentation materials will be available on the Altimmune website.

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021.

Scot Roberts, Ph.D., Chief Scientific Officer at Altimmune and Dr. Sarah K. Browne, Senior Director, Vaccine Development at Altimmune will give an oral presentation highlighting the Company’s AdCOVID™ intranasal COVID-19 vaccine candidate at the World Vaccine Congress, taking place May 4-7, 2021.

Dr. Scott Harris, Chief Medical Officer at Altimmune will give an oral presentation at the Chronic Hepatitis B Drug Development Virtual Summit, taking place May 5-6, 2021, during which he will provide an overview of HepTcell™, a novel peptide-based immunotherapeutic being developed by Altimmune for the treatment of chronic hepatitis B (CHB).

Details on the World Vaccine Congress presentation are as follows:

Title:	AdCOVID – A Single-Dose Intranasal Vaccine for COVID-19
Presenters:	Scot Roberts, Ph.D., Chief Scientific Officer at Altimmune Dr. Sarah K. Browne, Senior Director, Vaccine Development at Altimmune
Date:	May 4, 2021 (virtual pre-record available)

Details on the Chronic Hepatitis B Drug Development Virtual Summit presentation are as follows:

Title:	How We Can Achieve Success with Immunotherapeutics in the Treatment of Chronic Hepatitis B
Presenter:	Scott Harris M.D., Chief Medical Officer at Altimmune. Inc.
Date/Time:	May 5, 2021 at 1:30 pm ET

A copy of the presentation materials will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contacts:

Will Brown	Stacey Jurchison
Chief Financial Officer	Sr. Dir, Investor Relations
Phone: 240-654-1450	Phone : 410-474-8200
wbrown@altimmune.com	sjurchison@altimmune.com

FAQ

What is the significance of Altimmune's presentations at the scientific conferences in May 2021?

Altimmune will showcase its advancements in vaccine development and hepatitis B treatment at major conferences, emphasizing its commitment to addressing public health.

When is Altimmune presenting the AdCOVID intranasal vaccine?

Altimmune will present the AdCOVID intranasal vaccine at the World Vaccine Congress from May 4-7, 2021.

Who will present at the Chronic Hepatitis B Drug Development Virtual Summit?

Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on HepTcell, a novel treatment for chronic hepatitis B, on May 5, 2021.

Where can I find the presentation materials from Altimmune's conferences?

Presentation materials will be accessible in the Events section of Altimmune's website.

What are the key topics Altimmune will discuss at these conferences?

Altimmune will discuss the AdCOVID intranasal vaccine for COVID-19 and HepTcell for chronic hepatitis B treatment.